Fully equipped laboratories with a team of 75 members and up and running in less than 100 days
HYDERABAD, India, April 21, 2023 /PRNewswire/ — Sai Life Sciences, one of India’s fastest growing global contract research, development and manufacturing (CRO-CDMO) organizations, today announced the opening of Sai Schrödinger Research Laboratories (SSRL) at its RD campus in Hyderabad, India. The facility was inaugurated by Dr. Karen Akinsanya, President of RD, Schrödinger Inc. Therapeutics, in the presence of members of the management team from Schrödinger and Sai Life Sciences.
Opening the facility, Dr. Karen Akinsanya, explained: “We selected Sai Life Sciences as our CRO late last year, and we are very pleased that they are now ready to start working on our programs with a highly experienced and dedicated team. in a state- Sai Life Sciences will play an important role in advancing our drug discovery and early development activities, and we look forward to working closely together.”
In January 2023, Sai Life Sciences signed a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapies and materials are discovered, to establish SSRL in Hyderabad, India. Soon after, Sai Life Sciences began construction of the facility along with the recruitment of scientific staff, to carry out the project in an accelerated time frame.
Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, commented: “Our collaboration with Schrödinger marks an exciting new beginning for us at Sai Life Sciences, with a dedicated facility to support multiple discovery programs. The confidence they have that we have deposited with us is a testament to the advances we have made in the scale, scope and depth of our integrated drug discovery capabilities. I look forward to a productive collaboration.”
On the occasion of this inauguration, Dr. Karen Akinsanya and Krishna Kanumuri met with leading officials representing the Hon. Minister of Industry and Commerce, Government of Telangana, Shri KT Rama Rao, to brief them on the nature of the collaboration and the role Sai Schrödinger Research Laboratories (SSRL) will help advance drug discovery and development.
Established within the Sai Life Sciences research and development campus in Genome Valley, SSRL is a facility dedicated to integrated discovery workflows including medicinal and synthetic chemistry, in vitro biology, and process chemistry. SSRL will access other Sai capabilities such as ADME in vitro and PK in vivo as needed. The relationship will support the advancement of programs that take advantage of Schrödinger’s validated computing platform. Currently, SSRL has 75 full-time equivalent (FTE) employees in medicinal chemistry, biology, process chemistry, and analytical chemistry.
About Sai Life Sciences
Sai Life Sciences is a full-service CRO-CDMO working with more than 200 innovative pharmaceutical and biotech companies worldwide to accelerate the discovery, development, and commercialization of complex small molecules. The company has more than 2,600 employees at its facilities in India, the United Kingdom and the United States. Sai Life Sciences is a private company and is backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com/
Photo: https://mma.prnewswire.com/media/2059072…Logo: https://mma.prnewswire.com/media/1044186…
View original content: https://www.prnewswire.com/es/comunicados-de-prensa/sai-life-sciences-abre-ssrl-un-centro-de-investigacion-exclusivo-para-schrodinger-en-su-campus-de-id-de-hyderabad-301803825.html
